(Q41695078)

7 October 2017

title

Effectiveness research and implications for study design: sample size and statistical power (English)

1 reference

7 October 2017

0 references

Sturm R

1

1 reference

7 October 2017

Unützer J

series ordinal

2

1 reference

7 October 2017

Katon W

series ordinal

3

1 reference

7 October 2017

publication date

1 July 1999

1 reference

General Hospital Psychiatry

7 October 2017

published in

1 reference

7 October 2017

volume

21

1 reference

7 October 2017

issue

4

1 reference

7 October 2017

page(s)

274-283

1 reference

Cost-effectiveness comparisons using "real world" randomized trials: the case of new antidepressant drugs.

7 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2899%2900024-9

7 January 2021

Treatment research at the crossroads: the scientific interface of clinical trials and effectiveness research

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2899%2900024-9

7 January 2021

Towards a reduction in publication bias

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2899%2900024-9

7 January 2021

Empowering research: statistical power in general practice research

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2899%2900024-9

7 January 2021

Collaborative management to achieve treatment guidelines. Impact on depression in primary care

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2899%2900024-9

7 January 2021

Treatment costs, cost offset, and cost-effectiveness of collaborative management of depression.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2899%2900024-9

7 January 2021

Impact of improved depression treatment in primary care on daily functioning and disability

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2899%2900024-9

7 January 2021

The MOS 36-ltem Short-Form Health Survey (SF-36)

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2899%2900024-9

7 January 2021

How expensive are unlimited substance abuse benefits under managed care?

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2899%2900024-9

7 January 2021

Mental health and substance abuse parity: a case study of Ohio's state employee program

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2899%2900024-9

7 January 2021

Costs and incentives in a behavioral health carve-out

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2899%2900024-9

7 January 2021

Care for depression in a changing environment

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2899%2900024-9

7 January 2021

The logged dependent variable, heteroscedasticity, and the retransformation problem.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2899%2900024-9

7 January 2021

Sample sizes for studies using the short form 36 (SF-36)

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2899%2900024-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS0163-8343%2899%2900024-9

1 reference

7 January 2021

The design of Partners in Care: evaluating the cost-effectiveness of improving care for depression in primary care

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2899%2900024-9

7 January 2021

Statistical power of psychological research: what have we gained in 20 years?

1 reference

https://api.crossref.org/works/10.1016%2FS0163-8343%2899%2900024-9

7 January 2021

10.1016/S0163-8343(99)00024-9

Identifiers

DOI

1 reference

7 October 2017

1 reference